Drug Regulatory Systems in Comparative Perspective: A Tri-National Study of the United States, the Philippines, and Ghana

Fuente: Zenodo
Saved in:
Bibliographic Details
Main Author: Abishek R., Deevan Paul A.*
Format: Recurso digital
Published: Zenodo 2025
Subjects:
Online Access:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1866901949772726272
author Abishek R., Deevan Paul A.*
author_facet Abishek R., Deevan Paul A.*
contents <p><span>Making sure that medicinal products are safe, effective, and of guaranteed quality is crucial for public health protection, which is achieved through pharmaceutical regulation. This study compares the pharmaceutical regulatory systems of the United States, the Philippines, and Ghana, highlighting differences in structure, processes, and capacity. The U.S. FDA is a global standard, with robust approval pathways (IND, NDA, ANDA), strong post-marketing surveillance, and international harmonization. The Philippine FDA is undergoing reform, adopting the ACTD for ASEAN harmonization, but faces infrastructure and resource challenges. Ghana’s FDA has achieved WHO GBT Maturity Level 3 and engages in AMRH initiatives, though funding and technical limitations persist. The analysis underscores the need for ongoing investment in regulatory modernization and capacity building, especially in low- and middle-income countries.</span></p>
format Recurso digital
id zenodo_https___doi_org_10_5281_zenodo_15634462
institution Zenodo
language
publishDate 2025
publisher Zenodo
record_format zenodo
spellingShingle Drug Regulatory Systems in Comparative Perspective: A Tri-National Study of the United States, the Philippines, and Ghana
Abishek R., Deevan Paul A.*
CTD, ACTD, WHOGBT, USFDA, NDA, ANDA, FDA
<p><span>Making sure that medicinal products are safe, effective, and of guaranteed quality is crucial for public health protection, which is achieved through pharmaceutical regulation. This study compares the pharmaceutical regulatory systems of the United States, the Philippines, and Ghana, highlighting differences in structure, processes, and capacity. The U.S. FDA is a global standard, with robust approval pathways (IND, NDA, ANDA), strong post-marketing surveillance, and international harmonization. The Philippine FDA is undergoing reform, adopting the ACTD for ASEAN harmonization, but faces infrastructure and resource challenges. Ghana’s FDA has achieved WHO GBT Maturity Level 3 and engages in AMRH initiatives, though funding and technical limitations persist. The analysis underscores the need for ongoing investment in regulatory modernization and capacity building, especially in low- and middle-income countries.</span></p>
title Drug Regulatory Systems in Comparative Perspective: A Tri-National Study of the United States, the Philippines, and Ghana
topic CTD, ACTD, WHOGBT, USFDA, NDA, ANDA, FDA
url https://doi.org/10.5281/zenodo.15634462